Mazen Zaarour, MD

Hematologist & Oncologist @AdventHealth @Tulane grad⚜️ Views are my own

[Fabrizio Romano @FabrizioRomano]

Getty Images official picture. Christian Eriksen seems conscious. All prayers and thoughts with Chris and his family ❤️🙏🏻🇩🇰

[Mazen Zaarour, MD @Mzaarour09]

@DrKarineTawagi Congratulations

[Neeraj Agarwal, MD, FASCO @neerajaiims]

#ASCO21 @ASCO Plenary #LBA4 : VISION trial just presented 👏👏177Lu-PSMA-617 is new SOC in “PSMA positive” mCRPC #prostatecancer with prior novel AR inhibitors + taxanes👉Reduces risk of progression by 60% & of death by 38% @Morr316 @oncoalert @PCF_Science @urotoday

[Mazen Zaarour, MD @Mzaarour09]

@weoncologists Thank you! 💔

[Mazen Zaarour, MD @Mzaarour09]

@GIcancerDoc God protect Lebanon! So sad

[Mazen Zaarour, MD @Mzaarour09]

@Cancer_talks Congrats man

[Mazen Zaarour, MD @Mzaarour09]

@PBarataMD @ASCO @neerajaiims @montypal @GUONCGarciaJA @PGrivasMDPhD @koshkin85 @OncLive Great news indeed!

[Mazen Zaarour, MD @Mzaarour09]

@saramatarmd You know more than you think you know. It’s no different than fellowship. You still have mentors and experts to guide you if needed.

[Mazen Zaarour, MD @Mzaarour09]

Same here! Feels like yesterday!

[Sara Matar @saramatarmd]

@ADesaiMD 2nd anniversary here 🎉 I joined during #ASCO2018 because of colleague @Mzaarour09 , crazy that I joined @Twitter because of @ASCO

[Mazen Zaarour, MD @Mzaarour09]

@Cancer_talks 100%

[Tanios Bekaii-Saab, MD @GIcancerDoc]

Practice changing !
Atezolizumab plus Bevacizumab in Unresectable #Hepatocellular #Carcinoma @NEJM https://t.co/5GXm1g7nmR

[FDA Oncology @FDAOncology]

Today FDA granted accelerated approval to a new dosing regimen of 400 mg every six weeks for pembrolizumab (KEYTRUDA®, Merck) across all currently approved adult indications, in addition to the current 200 mg every three weeks dosing regimen https://t.co/CbtVXFeAzL

[OncLive.com @OncLive]

Nivolumab Plus Cabozantinib Improves OS in CheckMate-9ER Frontline RCC Trial @DrChoueiri @DanaFarber @harvardmed #kcsm #rcc https://t.co/nks5z8SPxL

[Gil Morgan, MD @weoncologists]

Just out📣 @US_FDA 🇺🇸grants Breakthrough therapy designation& submission of application to avelumab🧪in 1️⃣st line maintenance of locally advanced/metastatic urothelial carcinoma based on interim analysis of JAVELIN Bladder 100 trial🔬which met OS endpoint https://t.co/HmvrCjUvMw

[NEMR @NEMRCOMEDY]

The new video is up. It's time to discover our new leaders. Watch it. If you agree, then spread the word. Everywhere. Leave no stone unturned. I cannot in any way whatsoever pull this off without you.

Instagram: https://t.co/ZKCyZM5hZC

FaceBook: https://t.co/V0BQh16hFD

[ASCO @ASCO]

#ASCO19 Plenary Coverage: Maintenance Olaparib Improved PFS in Patients With BRCA+ Pancreatic Cancer https://t.co/kyaNGjwAKO #ASCOdailynews

[Fatima Karzai, M.D. @FatimaKarzai]

Treatment options in metastatic castrate-sensitive prostate cancer; chemo vs. abiraterone or enzalutamide. Biomarkers needed to help stratify. #ENZAMET #ASCO19 #mCSPC #plenarysession

[Mazen Zaarour, MD @Mzaarour09]

@trailblazers @bosnianbeast27 Get well soon big fella! @bosnianbeast27